Search clinical trials for: meningococcal B rLP2086 vaccine candidate

Total 640 results

Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

Meningitis, Meningococcal

Australia
Pfizer

Terminated

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Meningitis, Meningococcal

Spain
Pfizer

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Meningitis, Meningococcal

Poland, Spain, Australia
Prof. Elizabeth Miller
Novartis Vaccines

Completed

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults (MenOccy)

Meningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup W

United Kingdom
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
Novartis Vaccines

Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Meningococcal Infections | Meningococcal Meningitis

Argentina, Chile, Czech Republic, Hungary, Italy
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
U.S. Army Medical Research and Development Command

Completed

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine (HOPS)

Meningococcal Infection, Group B

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation

United States, Puerto Rico
ANRS, Emerging Infectious Diseases

Completed

Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers (VRI01)

HIV Infection

France
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Meningitis, Meningococcal, Serogroup B

United States
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Recruiting

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

Healthy Volunteers

China
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

Phase Ib Trial of MSP3 LSP in Children in Tanzania (MSP3TN)

Malaria

Tanzania
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Meningococcal Disease | Meningococcal Meningitis

Chile, Colombia, Panama
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Infections, Meningococcal

Mexico, Argentina
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

Infections, Meningococcal
University of North Carolina, Chapel Hill
North Carolina Translational and Clinical Sciences Institute

Completed

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine (4CMenB)

Neisseria Gonorrhoeae Infection

United States
Public Health England

Completed

Meningococcal B Vaccination in University Students (MNB3)

Neisseria Meningitidis Serogroup B

United Kingdom
Pfizer

Completed

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Meningococcal B Disease

Australia, Poland, Finland, Czechia
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Invasive Meningococcal Disease

United States, Poland
Novartis Vaccines

Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Meningococcal Disease | Meningococcal Meningitis

Chile
Novartis Vaccines

Completed

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Meningococcal Disease

United States
Novartis Vaccines

Completed

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Healthy

United Kingdom
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guizhou Center for Disease Control... and other collaborators

Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Meningitis | Meningococcal Infections | Meningococcal Meningitis

China
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Healthy Volunteers | Meningococcal Infection | Meningococcal Immunisation

United States, Puerto Rico
Public Health England
Institute of Child Health; National Institute of Biological Standards and Control

Completed

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (Sched2)

Pneumococcal Infections | Meningococcal Infections

United Kingdom
Beijing Minhai Biotechnology Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

Meningitis

China
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Meningococcal Disease | Meningococcal Meningitis

Australia, Canada
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Meningococcal Disease

Korea, Republic of
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

Healthy Population

China
Novartis Vaccines

Completed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Meningococcal Disease | Meningococcal Meningitis

Spain, Italy, United Kingdom, Czech Republic
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Not yet recruiting

A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

Meningococcal Meningitis

China
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

Tuberculosis

Philippines
National Institute of Allergy and Infectious Diseases...

Recruiting

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

Gonococcal Infection

United States, Thailand, Malawi
GlaxoSmithKline

Completed

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Poland, United Kingdom
GlaxoSmithKline

Completed

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Influenza

Belgium
GlaxoSmithKline
Region of Wallonia; Public Private Partnership with Institute for Medical Immunology...

Completed

Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

Hepatitis B

Belgium
Jiangsu Province Centers for Disease Control and...
Institute of Medical Biology, Chinese Academy of Medical Sciences

Active, not recruiting

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

Hand, Foot and Mouth Disease

China
Takeda

Completed

Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

Dengue Fever

Singapore
Chiron Corporation

Unknown

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

Meningococcal Disease; Meningococcal Meningitis

United Kingdom
GlaxoSmithKline

Active, not recruiting

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Infections, Meningococcal

United States, Italy
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Respiratory Synctial Virus Infections

United Kingdom

3

Subscribe